Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Science...(as developed a specialized shRNA designa...),Health

Date:10/22/2007

as developed a specialized shRNA design algorithm that greatly enhances the ability to select highly functional gene targeting sequences," added Jardine. "Alternative technologies frequently produce shRNA sequences that are ineffective at silencing the targeted genes, while causing high levels of unintended gene silencing that can lead to flawed experimental results."

By combining shRNA with Lentigen's proprietary viral vector delivery system, the gene silencing sequence is integrated into the host cell genome. This creates permanent gene silencing that cannot be achieved with synthetic siRNAs. Permanent gene silencing is crucial in many types of experiments, including those that examine complex gene networks in drug development and neurobiology.

Dr. Boro Dropulic, founder and chief executive officer of Lentigen, said, "By linking Lentigen's lentiviral technology and production capabilities with the RNAi expertise of Thermo Fisher Scientific, we are giving scientists a new tool that enables a much broader range of experiments involving gene silencing."

Thermo Scientific Dharmacon SMARTvector shRNA Lentiviral Particles can be ordered at http://www.thermo.com/dharmacon .

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With an annual revenue rate of more than $9 billion, we employ 30,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industri
'/>"/>

SOURCE Thermo Fisher Scientific Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
4. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
6. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
7. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
8. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
9. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
10. Inspire Announces Presentations at Two European Scientific Conferences
11. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting